3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Neoplasms
6
Leukemia
5
Neoplasms by Histologic Type
4
Myeloproliferative Disorders
4
Leukemia, Myeloid
4
Hematologic Diseases
4
Carcinoma, Non-Small-Cell Lung
4
Bone Marrow Diseases
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Leukemia, Myeloid, Chronic-Phase
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Piebaldism
1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Malignant Hepatobiliary Neoplasm
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Carcinoma, Squamous Cell
1
Blast Crisis
1
Adenocarcinoma of Lung
1
Interventions
Sunitinib
16
Imatinib Mesylate
13
nilotinib
8
ripretinib
4
regorafenib
4
avapritinib
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
pexidartinib
2
pembrolizumab
2
Bevacizumab
2
trametinib
1
tinostamustine
1
spartalizumab
1
romidepsin
1
ponatinib
1
pazopanib
1
palbociclib
1
olaratumab
1
guadecitabine
1
ferric carboxymaltose
1
epacadostat
1
dabrafenib
1
cediranib
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sorafenib
1
STA 9090
1
Observation
1
Iron-Dextran Complex
1
Indocyanine Green
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Gastrointestinal Stromal Tumors
×
ponatinib
×
Clear all
NCT01874665
2018-05-18
GIST
Takeda
Phase 2
Completed
45 enrolled
21 charts